Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8564
|
| pubmed:dateCreated |
1987-11-17
|
| pubmed:abstractText |
24 Chinese children aged 1.5-5 years and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B virus DNA polymerase (HBV DNAp), and HBV DNA on at least three occasions in the 6 months before the trial were randomised to receive either vitamin B complex or intramuscular recombinant alpha 2-interferon (r-IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks. In all 12 subjects receiving r-IFN, HBV DNAp and HBV DNA levels fell during the course of r-IFN injections. Within 4 weeks of cessation of r-IFN injection, the HBV DNAp and HBV DNA returned to pre-trial levels except in 2 subjects, in whom loss of HBV DNAp and HBV DNA was sustained for up to 18 months from onset of the trial. 1 child lost HBeAg at 18 months. 2 of the 12 children in the placebo group also had a sustained loss of HBV DNAp and HBV DNA during the 18 months, with 1 child losing HBeAg at 18 months. All 24 subjects remained positive for HBsAg. r-IFN produced very slight side-effects except for pyrexia and the "flu" syndrome, both of which showed rapid tachyphylaxis. In the dose given r-IFN was safe but had no long-term beneficial effects on HBsAg carriage in Chinese children.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Directed DNA Polymerase,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0140-6736
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
17
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
877-80
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2889081-Carrier State,
pubmed-meshheading:2889081-Child, Preschool,
pubmed-meshheading:2889081-Clinical Trials as Topic,
pubmed-meshheading:2889081-DNA, Viral,
pubmed-meshheading:2889081-DNA-Directed DNA Polymerase,
pubmed-meshheading:2889081-Female,
pubmed-meshheading:2889081-Follow-Up Studies,
pubmed-meshheading:2889081-Hepatitis B,
pubmed-meshheading:2889081-Hepatitis B Surface Antigens,
pubmed-meshheading:2889081-Hepatitis B virus,
pubmed-meshheading:2889081-Hong Kong,
pubmed-meshheading:2889081-Humans,
pubmed-meshheading:2889081-Infant,
pubmed-meshheading:2889081-Injections, Intramuscular,
pubmed-meshheading:2889081-Interferon Type I,
pubmed-meshheading:2889081-Male,
pubmed-meshheading:2889081-Prospective Studies,
pubmed-meshheading:2889081-Random Allocation,
pubmed-meshheading:2889081-Recombinant Proteins
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children.
|
| pubmed:affiliation |
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|